Abstract:Combinational antiretroviral therapy (cART) suppresses human immunodeficiency virus type 1 (HIV-1) viral replication and pathogenesis in acquired immunodeficiency syndrome (AIDS) patients. However, HIV-1 remains in the latent stage of infection by suppressing viral transcription, which hinders an HIV-1 cure. One approach for an HIV-1 cure is the "shock and kill" strategy. The strategy focuses on reactivating latent HIV-1, inducing the viral cytopathic effect and facilitating the immune clearance for the elimination of latent HIV-1 reservoirs. Here, we reported that the H3K4 trimethylation (H3K4me3)-specific demethylase KDM5A/B play a role in suppressing HIV-1 Tat/LTR-mediated viral transcription in HIV-1 latent cells. Furthermore, we evaluated the potential of KDM5-specific inhibitor JQKD82 as an HIV-1 "shock and kill" agent. Our results showed that JQKD82 increases the H3K4me3 level at HIV-1 5' LTR promoter regions, HIV-1 reactivation, and the cytopathic effects in an HIV-1-latent T cell model. In addition, we identified that the combination of JQKD82 and AZD5582, a non-canonical NF-κB activator, generates a synergistic impact on inducing HIV-1 lytic reactivation and cell death in the T cell. The latency-reversing potency of the JQKD82 and AZD5582 pair was also confirmed in peripheral blood mononuclear cells (PBMCs) isolated from HIV-1 aviremic patients and in an HIV-1 latent monocyte. In latently infected microglia (HC69) of the brain, either deletion or inhibition of KDM5A/B results in a reversal of the HIV-1 latency. Overall, we concluded that KDM5A/B function as a host repressor of the HIV-1 lytic reactivation and thus promote the latency and the survival of HIV-1 infected reservoirs.

Histone deacetylase inhibitor MC1293 induces latent HIV-1 reactivation by histone modification in vitro latency cell lines.

Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

Dilazep Synergistically Reactivates Latent HIV-1 in Latently Infected Cells.

Histone chaperone CAF-1 promotes HIV-1 latency by leading the formation of phase-separated suppressive nuclear bodies

Histone Deacetylase Inhibitor Scriptaid Reactivates Latent Hiv-1 Promoter By Inducing Histone Modification In In Vitro Latency Cell Lines

Gp120 Binding with DC-SIGN Induces Reactivation of HIV-1 Provirus Via the NF-κB Signaling Pathway

HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells.

Identify Potential Regulators in Hiv-1 Latency by Joint Microrna and Mrna Analysis

Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections

Selective Histonedeacetylase Inhibitor M344 Intervenes in HIV-1 Latency Through Increasing Histone Acetylation and Activation of NF-kappaB.

CBP/p300 lysine acetyltransferases inhibit HIV-1 expression in latently infected T-cells

Histonedeacetylase Inhibitor Oxamflatin Increase Hiv-1 Transcription by Inducing Histone Modification in Latently Infected Cells

Progress and Challenges in the Use of Latent HIV-1 Reactivating Agents

Involvement of Histone Methyltransferase GLP in HIV-1 Latency Through Catalysis of H3K9 Dimethylation.

Chidamide, a Histone Deacetylase Inhibitor-Based Anticancer Drug, Effectively Reactivates Latent HIV-1 Provirus.

Quercetin Synergistically Reactivates Human Immunodeficiency Virus Type 1 Latency by Activating Nuclear Factor‑κb.

Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment

KDM5A/B promotes HIV-1 latency and KDM5 inhibitors promote HIV-1 lytic reactivation

Advances in structure-activity relationships of HDAC inhibitors as HIV latency-reversing agents

KDM5A/B contribute to HIV-1 latent infection and survival of HIV-1 infected cells